Clinical study evaluating the long term safety of amifampridine phosphate in patients with MuSK antibody and AChR antibody positive myasthenia gravis Clinical study evaluating the long term safety of amifampridine phosphate in patients with MuSK anti ...
Long term safety study of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis patients - MSK-003 Long term safety study of amifampridine phosphate in patients with MuSK antibody positive and AChR a ...
MuSK antibody and AChR antibody positive myasthenia gravis MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] MuSK antibody and AChR antibody positive myasthenia gravis MedDRA version: 21.1;Level: PT;Classifica ...
Clinical study evaluating the effect of Amifampridine phosphate in patients with MuSK antibody positive myasthenia gravis, and a sample of AchR antibody positive myasthenia gravis patients Clinical study evaluating the effect of Amifampridine phosphate in patients with MuSK antibody posit ...
A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients - MSK-002 A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosp ...